Yin-Ling Lin

Title: Innovations of Yin-Ling Lin in HCV Research

Introduction

Yin-Ling Lin is a notable inventor based in Emeryville, CA (US), recognized for his contributions to the field of hepatitis C virus (HCV) research. With a total of 2 patents, Lin has made significant strides in developing methods to stimulate immune responses against HCV.

Latest Patents

Lin's latest patents include innovative approaches to HCV fusion polypeptides. The first patent provides HCV fusion polypeptides that consist of truncated or full-length HCV NS5 polypeptides, along with a portion of the HCV NS2 polypeptide. These polypeptides are fused to at least one other HCV epitope derived from different regions of the HCV polyprotein. This invention aims to stimulate an immune response to HCV, particularly activating HCV-specific T cells, including both CD4+ and CD8+ T cells. The second patent describes methods for activating HCV-specific T cells through the administration of HCV protein compositions, followed by a viral vector containing nucleic acid encoding HCV epitopes. These methods can also incorporate immunostimulatory nucleic acids and other adjuvants to enhance immune responses.

Career Highlights

Throughout his career, Lin has worked with prominent companies such as Novartis AG and Novartis Vaccines & Diagnostics GmbH. His work in these organizations has contributed to advancements in vaccine development and diagnostics for infectious diseases.

Collaborations

Lin has collaborated with esteemed colleagues, including Michael Houghton and Angelica Medina-Selby, who have also made significant contributions to the field of virology and immunology.

Conclusion

Yin-Ling Lin's innovative work in HCV research has the potential to lead to significant advancements in immunotherapy and vaccine development. His patents reflect a commitment to enhancing our understanding and treatment of hepatitis C.